Overview
No. Injectable and infusible NAD+ is not an FDA-approved drug product, and there is no FDA-approved NAD+ product for the uses it is commonly sought for.
That is a clear answer, and on its own it is less informative than it sounds — because "not FDA-approved" covers several quite different situations, and knowing which one applies is what actually tells you something.
| Form | Regulatory position |
|---|---|
| Injectable / infusible NAD+ | Not FDA-approved. Prepared by compounding pharmacies |
| Nicotinamide riboside (NR) | Marketed as a dietary supplement |
| Nicotinamide mononucleotide (NMN) | Contested. FDA has taken the position it is excluded from the supplement definition |
| Niacin (vitamin B3) | An established vitamin. Also an approved prescription drug at higher strengths for lipids |
| Nicotinamide | An established vitamin, widely available |
The distinction that matters most: FDA approval means the agency has reviewed evidence of safety and effectiveness for a specific use, and reviews the manufacturing. Compounded means a pharmacy prepared it — lawful under defined conditions, but without that review. Dietary supplement means a third category with different rules again, where products are not approved before sale.
None of those three is a verdict on whether something works. They describe what has and has not been reviewed.
What "FDA-approved" actually means
Approval is specific and it is narrower than most people assume.
A drug is approved for a particular use, at a particular strength, in a particular population, on the basis of submitted evidence of safety and effectiveness. The manufacturing facility is inspected and the product is made to defined standards with batch-to-batch consistency requirements.
Approval attaches to a product-and-indication pair, not to a molecule. This is why the same substance can be approved in one form and not another — niacin is the clearest example, being both an ordinary vitamin and, at prescription strengths, an approved lipid medication.
What approval does not mean is that everything unapproved is ineffective or unsafe. A great deal of legitimate medicine happens off-label with approved products, and compounding exists for real clinical reasons. It means a specific review has not happened.
What "compounded" means here
Injectable NAD+ is prepared by a compounding pharmacy — a pharmacy making a preparation for a patient rather than a manufacturer producing an approved product.
Compounding is lawful and long-established. It exists so that patients who cannot use an available approved product — an allergy to an excipient, a strength that is not manufactured, a supply shortage — can still be treated.
What it means practically:
Not FDA-reviewed for safety, effectiveness or consistency between batches.
Not manufactured under the same standards as an approved drug product, though compounding pharmacies are regulated and are subject to their own requirements — and there is a meaningful difference between a state-licensed 503A pharmacy and a 503B outsourcing facility registered with the FDA, which operates under stricter manufacturing standards.
Worth asking about. Where a preparation is made, and under which of those categories, is a reasonable question to ask any provider administering it.
The regulatory position on NAD+ specifically has been the subject of ongoing FDA review in the context of which substances may be used in compounding. That position has developed over time and continues to, which is why anyone offering this treatment should be tracking it rather than assuming.
Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product.
The oral precursors sit in a different system
Dietary supplements are regulated under a separate framework, and it works almost the opposite way round.
Supplements do not require FDA approval before being sold. Manufacturers are responsible for their own safety substantiation and labeling. The FDA's role is largely after the fact — acting on products already on the market that turn out to be unsafe or misbranded.
Which means "available on a shelf" carries much less information than people assume. Independent testing across the supplement category has repeatedly found products whose content differs from the label.
NR is marketed in this category and has notifications on record with the FDA regarding its use in supplements.
NMN is the interesting case. The FDA has taken the position that NMN is excluded from the dietary supplement definition, on the basis that it was authorized for investigation as a new drug before being marketed as a supplement. That position has been disputed by industry and has affected NMN's availability. This is the most changeable fact on this page.
Niacin and nicotinamide are ordinary vitamins with established status, and niacin at prescription strengths is separately an approved medication.
What this should and should not change
What it should change: ask where a preparation is made and under what category. Ask what monitoring accompanies it. Treat "available for sale" as telling you about regulatory category rather than about evidence.
What it should not change: the assumption that unapproved means unsafe, or that approved means proven for your situation. Neither follows.
And the practical version: a compounded preparation administered in a supervised clinical setting, by a provider who knows the regulatory position and monitors you, is a different proposition from an unlabeled vial bought online. The regulatory category is the same. Everything else is not.
Frequently asked questions
Is NAD+ FDA-approved? No. Injectable and infusible NAD+ is not an FDA-approved drug product. It is prepared by compounding pharmacies.
Does that mean it is unsafe? Not by itself. It means the FDA has not reviewed it for safety and effectiveness in the way it reviews an approved drug. Those are different statements.
What about NAD+ supplements? Oral products supply precursors rather than NAD+ itself, and they are regulated as dietary supplements, which do not require approval before sale.
Why is NMN harder to find? The FDA has taken the position that NMN is excluded from the dietary supplement definition because it was authorized for investigation as a new drug. That position has been disputed and has affected availability.
What should I ask a provider? Where the preparation is compounded and under which category, what monitoring accompanies treatment, and what they expect it to do. Those three questions tell you most of what you need.
Where this fits in your plan
The regulatory status is a real thing to know, and it is a description of what has been reviewed rather than a verdict on what works.
What it should prompt is a set of questions about sourcing and supervision — which are reasonable to ask anywhere, and which we would rather you asked us than skipped. What NAD+ therapy involves here, and what it costs.
We measure first. Then we act.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
